The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
about
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292Protein kinase inhibitors against malignant lymphomaStatus of PI3K/Akt/mTOR pathway inhibitors in lymphomaIdelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.B-cell receptor signaling as a driver of lymphoma development and evolution.Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphomaA Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphomaPhase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLLPhosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.Signal transduction inhibitor therapy for lymphoma.Utility of mTOR inhibition in hematologic malignancies.Evi1 forms a bridge between the epigenetic machinery and signaling pathways.Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingThe phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.Syk inhibition with fostamatinib leads to transitional B lymphocyte depletionSelective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies.Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
P2860
Q24607479-0F9F25CC-8FA3-40F3-BD05-A321050DB6C1Q27009550-CC87DA87-2C1D-44AF-8EDA-40CF902E06EBQ27024212-B0EF631B-BE2B-48FE-938A-2BB04B05EF9CQ27026544-07842A4E-822D-4F4C-9C0D-0F0C1285FD09Q34009003-7B58E394-AD57-4A19-A7A8-67854EF50412Q34184717-A8A04017-56A0-4054-92E6-9FD18E37E8CAQ34398579-7F8E572B-718C-4A39-8142-BF77BFDF90BAQ34448586-46F45C56-EAB2-4492-83E0-69B3C6C12A48Q34617756-788A7558-D8C0-49F0-9BA9-FC0B0D0274A7Q35142268-91BF0725-B562-43B5-9EF0-435975A3133DQ35525569-08A3BC39-D439-42BC-AA81-49FAE6997E0DQ35859219-127F4E97-F7D7-496E-A8D1-306314199FF0Q36135185-3DD2AFBA-A6C8-4142-8CA9-88EDD1B35A0DQ36404778-FCA0B6AB-6C19-414F-9F7F-01BAE140589AQ36737287-F25E6C91-C79A-4F72-BAAE-6D6CE9D520A4Q36862781-6DC417A3-847F-4130-9874-7289FD24BB02Q37132788-78BCF36A-EFF9-4922-BD65-AE542173A774Q37178611-2846BE08-1398-4651-AF5A-E9621C7C880BQ37613320-8880CE38-AC77-41B4-B9D7-6653127A97F0Q37829224-9F3FE227-9202-4791-BD91-EB01D0C1572CQ37883723-3C2F73BF-DDCD-4982-A2C5-EDE19FD7E472Q37906986-E6C50911-4033-4615-A77F-D771431C2785Q38012179-EE7E4DC2-E88F-431F-A3CF-252D61D2DE2DQ38069567-AEFE0CEE-6F19-4BF7-B47F-79A5C97262A4Q39722770-1A17F15F-E086-4D49-86E9-CBCBAC41CEEBQ42073989-BD47E8D3-4295-494B-8306-4789DECD435FQ42320922-CF05CE06-75CA-456F-B7AB-068D40AC5C02Q42432648-6CDC7DEA-6B21-4DBB-9FFC-F1294A73C94B
P2860
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The treatment of recurrent/ref ...... CLL cells into the circulation
@ast
The treatment of recurrent/ref ...... CLL cells into the circulation
@en
type
label
The treatment of recurrent/ref ...... CLL cells into the circulation
@ast
The treatment of recurrent/ref ...... CLL cells into the circulation
@en
prefLabel
The treatment of recurrent/ref ...... CLL cells into the circulation
@ast
The treatment of recurrent/ref ...... CLL cells into the circulation
@en
P2093
P2860
P356
P1433
P1476
The treatment of recurrent/ref ...... CLL cells into the circulation
@en
P2093
Betsy R LaPlant
Clive S Zent
Ivana N Micallef
Patrick B Johnston
Thomas E Witzig
Thomas M Habermann
Timothy G Call
P2860
P304
P356
10.1002/CNCR.25005
P407
P577
2010-05-01T00:00:00Z